Psilocybin brain scan study completed in healthy adults
NCT ID NCT07050368
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 26 times
Summary
This early-stage study tested multiple doses of MLS101 (a low-dose psilocybin) in 20 healthy volunteers aged 18 to 55. Researchers used brain scans (fMRI) to see how the drug affects brain activity and checked for side effects. The goal was to gather safety and brain-imaging data to support future studies in people with neurological or psychiatric conditions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hammersmith Medicines Research (HMR)
London, NW10 7EW, United Kingdom
Conditions
Explore the condition pages connected to this study.